{'fraction_non_alphanumeric': 0.02485207100591716, 'fraction_numerical': 0.01301775147928994, 'mean_word_length': 5.934426229508197, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Successful Management of Humoral Hypercalcemia of Malignancy in A Patient with Ovarian Cancer

We present here successful treatment with bisphosphonate pamidronate of a 54-yearold patient with advanced ovarian cancer and humoral hypercalcemia of malignancy, followed by cytoreductive surgery and postoperative chemotherapy. Concentration of serum calcium increased to 16.8 mg/dL and parathyroid hormone-related protein (PTHrP)-intact was remarkably elevated. Interestingly, the 1,25-dihydroxyvitamin D (1,25-DHD) was high in this case. Treatment with bisphosphonate pamidronate was effective for the improvement of hypercalcemia so that she could undergo optimal surgery followed by postoperative chemotherapy. The histochemical examination of PTHrP using anti-human monoclonal antibody showed positive staining in the cancer cells of the ovary.